Implantable polymeric device for sustained release of dopamine agonist
AssigneeTitan Pharmaceuticals, Inc.
InventorsRajesh A. PATEL, Louis R. Bucalo, Lauren Costantini, Sofie Kleppner
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions, methods, and kits for treatment of Parkinson's disease and other conditions for which treatment with a dopamine agonist is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time. Dopamine agonist is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with dopamine agonist.
Claims56
An implantable device for administration of a dopamine agonist to a mammal in need thereof, comprising a dopamine agonist and a biocompatible, nonerodible polymeric matrix,
- wherein said dopamine agonist is encapsulated within said matrix, and wherein when said implantable device is implanted subcutaneously in said mammal, said dopamine agonist is continuously released in vivo over a sustained period of time through pores that open to the surface of said matrix at a rate that results in a plasma level of at least about 0.01 ng/ml at steady state.
An implantable device for administration of a dopamine agonist to a mammal in need thereof, comprising a dopamine agonist and a biocompatible, nonerodible polymeric matrix,
- wherein said dopamine agonist is encapsulated within said matrix, and
- wherein when said implantable device is subcutaneously implanted in a mammal, said dopamine agonist is continuously released in vivo over a sustained period of time through pores that open to the surface of said matrix at a rate of at least about 0.1 mg of dopamine agonist per day at steady state.
A method for administration of a dopamine agonist to a mammal in need thereof, the method comprising administering at least one implantable device subcutaneously,
- wherein each of said at least one implantable devices comprises a dopamine agonist encapsulated within a biocompatible, nonerodible polymeric matrix,
- wherein said dopamine agonist is continuously released in vivo from each of said at least one implantable devices over a sustained period of time through pores that open to the surface of said matrix at a rate that results in a plasma level of at least about 0.01 ng/ml at steady state.
A kit comprising at least one implantable device comprising a dopamine agonist encapsulated within a biocompatible, nonerodible polymeric matrix, wherein when said at least one implantable device is implanted subcutaneously in a mammal, said dopamine agonist is continuously released in vivo from each of said at least one implantable devices over a sustained period of time through pores that open to the surface of said matrix at a rate that results in a plasma level of at least about 0.01 ng/ml at steady state and instructions for use in a method of administration of a dopamine agonist to a mammal in need thereof.
Dependencies are inferred from the claim text.